Eli Lilly and Company (LLY)

LLY (NYSE:Drugs)
$60.43
pos +0.00
+0.00%
Today's Range: 59.62 - 60.45 | LLY Avg Daily Volume: 5,405,600
Last Update: 04/17/14 - 4:00 PM EDT
Volume: 0
YTD Performance: 18.49%
Open: $0.00
Previous Close: $59.96
52 Week Range: $47.53 - $60.46
Oustanding Shares: 1,119,713,084
Market Cap: 67,140,646,988
6-Month Chart
TheStreet Ratings Grade for LLY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 4 5 5
Moderate Buy 0 0 0 0
Hold 6 5 6 5
Moderate Sell 0 1 1 1
Strong Sell 2 3 2 3
Mean Rec. 2.38 2.87 2.59 2.74
Latest Dividend: 0.49
Latest Dividend Yield: 3.30%
Dividend Ex-Date: 02/12/14
Price Earnings Ratio: 13.75
Price Earnings Comparisons:
LLY Sector Avg. S&P 500
13.75 13.90 29.01
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
9.55% 5.15% 67.81%
GROWTH 12 Mo 3 Yr CAGR
Revenue 2.30 0.00 0.00
Net Income 14.60 -0.08 -0.03
EPS 18.00 -0.05 -0.02
Earnings for LLY:
EBITDA 6.99B
Revenue 23.11B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $0.70 $0.65 $2.80 $3.15
Number of Analysts 10 8 11 12
High Estimate $0.76 $0.69 $2.84 $3.45
Low Estimate $0.62 $0.58 $2.76 $2.78
Prior Year $1.14 $1.16 $4.15 $2.80
Growth Rate (Year over Year) -38.60% -43.86% -32.44% 12.41%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

updateEli Lilly upgraded at Jefferies

Apr 14, 2014 | 7:54 AM EDT

LLY upgraded to Hold from Underperform, Jefferies said. Material downside catalysts removed. $54 price target. 

bullishEli Lilly upgraded at BMO

Apr 8, 2014 | 8:01 AM EDT

LLY was upgraded from Underperform to Market Perform, BMO Capital said. $62 price target. Company has been executing well, versus low expectations. 

By

Jim Cramer

 | Mar 29, 2014 | 8:00 AM EDT

TheStreet's Jim Cramer says newer pharmaceutical companies, like Celgene (CELG), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN), should be bought on any weakness because they have the potential to perform extremely well and may be better buys than Pfizer, Merck, Bristol-Myers and Eli Lilly.

By

Gary Morrow

 | Feb 19, 2014 | 1:22 PM EST

And the stock now has layers of support in place.

bullishEli Lilly price target bumped at Jefferies

Feb 12, 2014 | 8:15 AM EST

ELI raised its number, Jefferies said. Strong performance in Cymbalta, Humalog, Alimta, and Cialis. $44 price target and Underperform rating. 

bearishLeerink Healthcare Conf.

Feb 12, 2014 | 7:10 AM EST

Leerink Swann Global Healthcare Conference (Day 1 of 2) - 02/12/14 - 02/13/14 New York, NY

By

Christopher Versace

 | Feb 11, 2014 | 11:00 AM EST

Medidata Solutions is focusing its cloud-computing offerings on the pharmaceutical industry.

bullishEli Lilly estimates, target increased at MKM

Jan 31, 2014 | 8:26 AM EST

LLY estimates were raised through 2018, MKM Partners said. Company is seeing higher sales. Buy rating and new $61 price target. 

bearishEli Lilly downgraded at BMO

Jan 8, 2014 | 8:12 AM EST

LLY was downgraded from Market Perform to Underperform, BMO Capital said. $50 price target. Expect lower results from the clinical pipeline in 2014. 

By

Doug Kass

 | Jan 7, 2014 | 8:04 AM EST
Let's take a look at the overnight and early-morning price action in the major asset classes.
There were nice reversal-type candles on the weekly charts of the major indices. The DOW a...
A number of stocks on my watch lists are attempting to form positive candles a key suppor...
While last week was a day to pull the plug and contemplate where the market was headed, I ...
Shares of TSLA have formed multiple hammer candles at a key level of support defined by: t...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.